Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TNF | P01375 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14381107 | 1.00 | MDM2 (0.53) | MDM2IDO1TLR2MDM4TP53 | |
| SCHEMBL10131781 | 1.00 | MDM2 (0.53) | MDM2IDO1TLR2MDM4TP53 | |
| SCHEMBL30954533 | 0.92 | MDM2 (0.51) | MDM2IDO1TLR2MDM4TP53 | |
| SCHEMBL30649315 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29768913 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29352017 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL120511 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL117964 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29792120 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF | |
| SCHEMBL29792372 | 0.92 | MDM2 (0.55) | MDM2TLR2MDM4TP53TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VITALIXIR (BEIJING) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| CN-118679179-B | Long-acting GLP-1 polypeptide compound, composition and application thereof | 内蒙古博睿精创科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-113614102-B | Novel polypeptides and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024160926-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX B.V. (NL) | 2024-08-08 | — | — | WO | disclosed |
| CN-118126124-A | Bioactive polypeptide with QRRAD structure, composition and application thereof | 深圳市肽金生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116650424-A | Novel polypeptide formulations and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230263896-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | VITALIXIR (BEIJING) CO., LTD (CN) | 2023-08-24 | — | — | US | disclosed |
| CN-116133677-A | Novel polypeptide formulations and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116113429-A | Novel polypeptides and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-4177263-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | Vitalixir (Beijing) Co., Ltd (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114891071-A | Novel polypeptides and therapeutic uses thereof | 鸿绪生物科技(嘉善)有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220127323-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF | VITALIXIR (BEIJING) CO., LTD (CN) | 2022-04-28 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VIP, GCG, GLS | MDM2 3544/4885IDO1 4248/4885TLR2 4130/4885 |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | MDM2 3228/4885IDO1 421/4885TLR2 3707/4885 |
| US-20220127323-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USES THEREOF | VIP, IAPP, LNPEP | MDM2 2956/4885IDO1 4099/4885TLR2 2668/4885 |
| US-20230263896-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | VIP, IAPP, LNPEP | MDM2 3429/4885IDO1 4210/4885TLR2 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.